Rinvoq ER (upadacitinib extended-release) is a Janus kinase (JAK) inhibitor designed to manage moderate to severe rheumatoid arthritis and other inflammatory diseases, including psoriatic arthritis and ankylosing spondylitis. By selectively inhibiting JAK enzymes, Rinvoq ER helps reduce inflammation and immune system overactivity that contribute to joint damage and symptoms. The extended-release formulation allows for convenient once-daily oral dosing. Patients on Rinvoq ER should be monitored regularly for potential side effects such as infections, changes in blood counts, liver enzyme elevations, and increased risk of blood clots. Usage should follow a healthcare provider’s guidance.